Superworth

Assembly Biosciences price to book ratio ASMB

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
1.3×
10-year median
2.2×
Against its 10-year history
32nd
percentile: 0 is its lowest day, 100 its highest
10-year range
0.3× to 21.6×
Peer median
1.9×

Assembly Biosciences' price to book ratio is 1.3× as of Oct 23, 2026.

That is below its ten-year median of 2.2×, lower than on 68% of days in the last ten years.

Over that time it ranged from 0.3× in Mar 2022 to 21.6× in Mar 2018.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.3×1.3×2.9×
20252.9×2.0×13.2×
20243.7×1.3×4.2×
20231.3×0.5×1.3×
20220.6×0.3×0.8×
20210.5×0.5×0.8×
20200.7×0.6×3.5×
20193.5×1.3×3.6×
20182.5×2.1×21.6×
201716.7×2.5×17.8×
20162.3×0.7×2.7×
20151.0×1.0×3.6×
20141.8×0.9×3.9×
20132.4×1.2×3.4×
20121.3×1.2×5.6×
20111.9×1.7×12.8×

Against its peers

Companies in Drug Manufacturers - General nearest Assembly Biosciences' size, closest first, today.

CompanyPrice to book ratio
ASMBAssembly Biosciences1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
NATRNatures Sunshine Products1.3×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Assembly Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.